Does Mounjaro Contain Semaglutide — and How Do the Two Medicines Actually Differ?

Step 1 (Understand what each medicine actually is

A question our prescribers hear most weeks is some version of: "I've been reading about Mounjaro and Wegovy) aren't they the same thing?" They aren't, and the distinction starts at the molecular level.

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist. It activates two gut-hormone pathways simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both receptors are involved in appetite signalling and blood-sugar regulation. Mounjaro is the only weight-management medicine licensed in the UK that targets both at once. More on how Mounjaro's mechanism compares is worth reading if the distinction matters to you clinically.

Semaglutide (Wegovy, for weight loss; Ozempic, for type 2 diabetes) is a single GLP-1 receptor agonist. It targets only the GLP-1 pathway. That is not a criticism (GLP-1 agonism is a well-established and effective mechanism) but it is a genuine pharmacological difference from tirzepatide. The NHS patient page on tirzepatide and the equivalent page on semaglutide set this out clearly for patients.

So to answer the headline question plainly: no, tirzepatide does not contain semaglutide, and if you have been wondering whether semaglutide is the same as Mounjaro, the two are not different doses of the same drug. They share a broad family resemblance (both are once-weekly injections, both slow gastric emptying, both reduce appetite) but they are distinct medicines from different manufacturers.

Step 2, Compare the trial evidence and UK licences

The table below summarises the key factual differences. Numbers are drawn from published clinical trial data and UK licensing documents.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, was the first large randomised head-to-head comparison: tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. Wegovy's newer 7.2mg dose (approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026) narrows that gap, though no head-to-head trial at 7.2mg has yet reported. The question of whether semaglutide is as effective as Mounjaro is more nuanced than any single figure suggests, because individual responses vary considerably.

Step 3, Know which semaglutide product is licensed for what

This is where confusion is most common. Semaglutide exists under three brand names in the UK, and their licences are not the same.

Wegovy (injection, 0.25mg up to 2.4mg or 7.2mg weekly) is licensed for weight management. Ozempic (injection) is semaglutide licensed for type 2 diabetes, not weight loss. Prescribing Ozempic for weight loss alone is off-licence; it also contributed to supply shortages that affected people who needed it for diabetes. The MHRA is clear on this distinction. And Wegovy tablets (oral semaglutide, approved by the MHRA on 11 June 2026 as the first oral GLP-1 licensed in the UK for weight management) are a third format, with a separate dosing schedule (1.5mg rising to 25mg daily). Patients sometimes ask whether Mounjaro contains semaglutide, and the straightforward answer is that none of these semaglutide products contain tirzepatide, and Mounjaro contains none of them.

For a fuller look at how the injectable versions sit alongside each other, our Wegovy vs Mounjaro comparison covers the practical differences in more depth, including the side-effect profiles and cost context. The UK pricing picture is also worth reading before making a decision.

Step 4, What this means for the clinical decision

Both medicines carry similar eligibility criteria for private prescribing: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A prescriber reviews your full medical history (not just your BMI) before recommending either. Things like prior GI conditions, medications that interact with oral absorption, personal preference about injection frequency, and how your body responds at the starter dose all feed into that conversation.

The side-effect profiles overlap: nausea, constipation, diarrhoea and indigestion are common with both, tending to be most noticeable when starting or after a dose increase. Tirzepatide's dual mechanism means the contraception note is specific to it: women taking oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, as pill absorption may be reduced. No equivalent evidence exists for semaglutide. Our clinical team discuss these details with every patient during the consultation process.

Which medicine suits you is genuinely a clinical decision, and one our prescribers make with you. Check your eligibility and start a free consultation, a GPhC-registered Independent Prescriber will review your answers the same day.